Edralbrutinib Recruiting Phase 2 Trials for Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04948788SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma